$96.9 Million is the total value of venBio Partners L.P.'s 4 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Sell | Apellis Pharmaceuticals, Inc | $72,482,000 | -8.4% | 3,294,654 | -8.0% | 74.78% | +53.3% | |
| VRNA | Verona Pharma PLCsponsored ads | $11,953,000 | -31.7% | 875,000 | 0.0% | 12.33% | +14.3% | |
| MNLO | Menlo Therapeutics Inc. | $11,868,000 | -78.4% | 1,461,552 | 0.0% | 12.24% | -63.8% | |
| Sell | Nabriva Therapeutics PLC | $619,000 | -94.2% | 177,957 | -91.6% | 0.64% | -90.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Apellis Pharmaceuticals, Inc | 5 | Q4 2018 | 77.1% |
| Verona Pharma PLC | 5 | Q4 2018 | 22.2% |
| Menlo Therapeutics Inc. | 4 | Q4 2018 | 33.9% |
| Nabriva Therapeutics PLC | 3 | Q2 2018 | 12.6% |
View venBio Partners L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-04-25 |
| 13F-HR | 2018-04-25 |
View venBio Partners L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.